Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

July 26, 2022

Study Completion Date

December 14, 2022

Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG

SPN-812

SPN-812 200 to 600 mg/day

Trial Locations (38)

10549

Altea Research Institute, Las Vegas

Bioscience Research, Mount Kisco

30030

iResearch Atlanta, Decatur

30060

Psych Atlanta, Marietta

30331

Atlanta Center for Medical Research, Atlanta

32217

Clinical Neuroscience Solutions, Inc, Jacksonville

32751

Florida Clinical Research Center, LLC, Maitland

32763

Medical Research Group of Central Florida, Orange City

32801

Clinical Neuroscience Solutions Inc., Orlando

32806

CNS Healthcare, Orlando

33024

Research Centers of America, Hollywood

33634

Meridien Research, Tampa

33805

Meridien Research, Lakeland

33912

Gulfcoast Research Center, Fort Myers

38119

Clinical Neuroscience Solutions, Memphis

63304

St. Charles Psychiatric Associates Midwest Research Center, Saint Charles

66211

Psychiatric Associates, Overland Park

68526

Alivation Research, LLC, Lincoln

73188

Paradigm Research Professionals, Oklahoma City

75231

FutureSearch Trials of Dallas, LLP, Dallas

77098

Houston Clinical Trials, Houston

77381

Family Psychiatry of the Woodlands, The Woodlands

78759

BioBehavioral Research of Austin P.C., Austin

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

90210

South California Research LLC, Beverly Hills

90502

Collaborative Neuroscience Network LLC, Torrance

90720

Pharmacology Research Institute, Los Alamitos

92078

Artemis Research Institue for Clinical Research, Riverside

Artemis Institute for Clinical Rearch, San Marcos

92103

Artemis Institute for Clinical Research, San Diego

92660

Pharmacology Research Institute, Newport Beach

92845

Collaborative Neuroscience Network, Garden Grove

98007

Northwest Clinical Trials, Bellevue

08009

Hassman Research Institute, Berlin

08002

Center for Emotional Fitness, Cherry Hill

08053

Hassmann Research Institute, Marlton

08540

Princeton Medical Institute, Princeton

10128r

The Medical Research Network LLC, New York

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT04143217 - Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | Biotech Hunter | Biotech Hunter